The BTF’s ASH Annual Meeting Review 2023 – Coeur d’Alene is a CME-accredited, in-person hematology conference featuring leading experts in the field. This conference allows professionals an opportunity to discuss current research and advances in the field of blood disorders and hematologic malignancies with colleagues and key opinion leaders. Expert faculty will place key abstract findings from the 64th ASH Annual Meeting into clinical context and discuss how the results may change the current standard of care. The goals of this conference are to review and critically assess practice-changing results of practice-changing clinical data and expert recommendations to optimize clinical outcomes for the patients.

This activity is planned and implemented by the Binaytara Foundation to educate hematologists/oncologists and others involved in the care of patients with hematologic malignancies and benign hematological disorders about the most important updates from the 64th American Society of Hematology (ASH) Annual Meeting in December 2022. Neither the Binaytara Foundation nor this activity is affiliated with the American Society of Hematology (ASH).


  • Hematologist/Oncologists
  • Oncology Oncology Physician Assistants/Nurse Practitioners
  • Oncology Pharmacists
  • Oncology Nurses


  • Review data presented at the 64th ASH Annual Meeting (2022) and discuss their application in clinical settings
  • Choose new therapeutic options for the treatment of blood disorders and hematologic malignancies, understanding appropriate indications, and contraindications to these therapeutic approaches.
  • Discuss the study design and primary endpoints of recently reported and ongoing trials that have influenced the changes in the standards of care for patients with blood disorders and hematologic malignancies.
  • Integrate evolving diagnostic, prognostic, and therapeutic approaches to the management of patients with blood disorders and hematologic malignancies.
  • Apply practical expertise gained from clinical situations emphasizing data-based approaches to patients with blood disorders and hematologic malignancies in community practice.